Quad Pill Poised to Become the Next One-Pill, Once-Daily Treatment for HIV

The single-tablet regimen — containing tenofovir, FTC, elvitegravir, and cobicistat — proved both safe and effective in two phase III trials presented at CROI 2012.

Interest in the investigational combination antiretroviral “Quad” tablet containing tenofovir, FTC, elvitegravir, and cobicistat has been fueled largely by results announced only in press releases. At the CROI 2012 meeting in Seattle, more-complete data were presented from two parallel, manufacturer-supported, phase III clinical trials — one comparing Quad with the fixed-dose combination of tenofovir/FTC/efavirenz (Atripla) and one comparing it with tenofovir/FTC + ritonavir-boosted atazanavir.

In the Quad versus Atripla study, presented by Paul Sax [Abstract 101], 700 treatment-naive, HIV-infected patients were randomized to one of the two single-tablet regimens. At week 48, 88% of Quad recipients and 84% of Atripla recipients had viral loa…

Author

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Charles B. Hicks, MD

Disclosures

Consultant / Advisory boardGilead Sciences; ViiV; Merck

RoyaltiesUpToDate, Inc.

Grant / Research supportNIH; Department of Health and Human Services

Quad Pill Poised to Become the Next One-Pill, Once-Daily Treatment for HIV

Topics

Author